Browse
Submit Data
Databases
API
Help

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A patient with neurofibromatosis type 1 and Charcot-Marie-Tooth disease type 1B.

ABSTRACT: We describe a patient with both neurofibromatosis type 1 and Charcot-Marie-Tooth disease type 1B. Although one might expect an overwhelming tumor burden due to the combination of these two disorders, the two mutations did not appear to interact.

SUBMITTER: Lancaster E

PROVIDER: S-EPMC2847649 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

A patient with neurofibromatosis type 1 and Charcot-Marie-Tooth disease type 1B.

Lancaster Eric E Elman Lauren B LB Scherer Steven S SS

Muscle & nerve 20100401 4

We describe a patient with both neurofibromatosis type 1 and Charcot-Marie-Tooth disease type 1B. Although one might expect an overwhelming tumor burden due to the combination of these two disorders, the two mutations did not appear to interact. ...[more]

PMID: 19918771

Similar Datasets

Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice.

Project description: Not available

| S-EPMC3620355 | biostudies-literature

Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B

Project description:Mutations in myelin protein zero (MPZ) are generally associated with Charcot-Marie-Tooth type 1B (CMT1B) disease, one of the most common forms of demyelinating neuropathy. Pathogenesis of some MPZ mutants, such as S63del and R98C, involves protein misfolding and retention in the endoplasmic reticulum (ER) of myelinating Schwann cells. To cope with proteotoxic ER-stress, Schwann cells mount an unfolded protein response (UPR) characterized by activation of the PERK, ATF6 and IRE1/XBP1 pathways. Previous studies have reported that targeting PERK pathway can mitigate the neuropathy in CMT1B mice. To unravel the role of the XBP1 pathway in normal myelination and in CMT1B, we generated mouse models of in which XBP1 is deleted specifically in Schwann cells. We observed that whereas XBP1 is dispensable for normal developmental myelination, myelin maintenance and remyelination after injury, the absence of XBP1 dramatically worsens the hypomyelination and the electrophysiological and locomotor parameters in young and adult CMT1B neuropathic animals. RNAseq analysis suggested that XBP1 exerts its adaptive function in large part via the induction of genes involved in misfolded protein degradation. Accordingly, the exacerbation of the neuropathy was accompanied by upregulation of ER-stress pathways and of IRE1-mediated RIDD signaling, suggesting that the activation of XBP1 plays a critical role in limiting mutant proteins toxicity, which cannot be compensated by other stress responses. Schwann cell specific overexpression of spliced XBP1 partially re-established Schwann cell proteostasis and attenuated CMT1B severity in vivo in both the S63del and R98C mouse models. In addition, the pharmacologic selective activation of XBP1 signaling ameliorated myelination in S63del dorsal root ganglia explants.

2024-01-15 | GSE252089 | GEO

Linkage and mutation analysis in an extended family with Charcot-Marie-Tooth disease type 1B.

Project description: Not available

| S-EPMC1050130 | biostudies-other

Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients.

Project description: Not available

| S-EPMC47877 | biostudies-other

Charcot-Marie-Tooth disease.

Project description: Not available

| S-EPMC2947101 | biostudies-literature

Expression data from a Charcot-Marie-Tooth 1B neuropathy mouse model

Project description:We have generated mouse models of real CMT1B mutations in the gene encoding for myelin protein zero (P0). One of these mutants, P0S63del is retained in the ER where it elicits an unfolded protein response (UPR). Genetic ablation of the UPR factor CHOP restores the motor capacity in S63del mice. We used microarray to decipher the molecular mechanism undelying the P0S63del neuropathy and the rescue in S63del/Chop null nerves. Sciatic nerves were dissected from WT, S63del, Chop null and S63del/Chop null mice at three different time points: (i) postnatal day 5 (P5) when myelination has just started and only the primary effects of the presence of the mutant protein should be detected; (ii) P28, around the peak of myelination, when all the downstream targets of CHOP should be activated; and (iii) 4 months, to check for secondary effects of the disease and because this was the time-point when the motor and morphological rescue due to the ablation of CHOP were clearly detectable.

2013-05-01 | E-GEOD-40610 | biostudies-arrayexpress

Intermediate Charcot-Marie-Tooth disease.

Project description: Not available

| S-EPMC5562560 | biostudies-other

Modeling the pathogenesis of Charcot-Marie-Tooth disease type 1A using patient-specific iPSCs

Project description:Here, human induced pluripotent stem cells (control-hiPSCs, CMT1A-hiPSCs, and PMP22-hiPSCs) were induced to differentiate to Schwann cells (control-SCs, CMT1A-SCs, and PMP22-SCs) through neural crest stage (control-NCSCs, CMT1A-NCSCs, and PMP22-NCSCs). We sequenced mRNA samples from Schwann cell differentiation of human pluripotent stem cells at 3 different stage to generate the gene expression profiles of these cells.

2018-02-14 | GSE97851 | GEO

Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.

Project description: Not available

| S-EPMC3752697 | biostudies-literature

An axon regeneration signature in a Charcot-Marie-Tooth disease type 2 patient.

Project description: Not available

| S-EPMC2716698 | biostudies-literature